Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

CAMP4 Therapeutics Corporation (CAMP) Stock · SELL · CRISIS | LOPJLB

CAMP4 Therapeutics Corporation (CAMP)

Healthcare · Biotechnology · NASDAQ · US

$3.77+1.89%Close

SELLCRISIS · day 3

CAMP▼ SELL

$3.77+1.89%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $80M
Beta: 0.21
P/E (TTM): -1.78

Short % float: 52.45%
Days to cover: 5.1
SI change: +47.1%

1W: -5.75%
1M: -13.13%

vs SPY 1W: -6.91%
vs SPY 1M: -16.13%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

Employees: 48
Headquarters: US
Founded: 2024
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 21.2M
Float: 13.1%

camp4tx.com ↗

Key executives

Joshua Mandel-Brehm — Chief Executive Officer, President & Director

Kelly Gold — Chief Financial Officer

Yuri Maricich — Chief Medical Officer

SEC filings

EDGAR · CIK 17367300 · CAMP

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish1666.7%

Neutral729.2%

Bearish14.2%

L $6.00Avg $10.50H $15.00

Target$10.50+178.51%

Last$3.77

ANALYST & RATINGS

LOADING…

Loading analyst data…

Company news

defenseworld.net · 13d ago

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages

defenseworld.net · 14d ago

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

seekingalpha.com · 14d ago

Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day Transcript

marketbeat.com · 14d ago

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

globenewswire.com · 33d ago

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

globenewswire.com · 34d ago

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

globenewswire.com · 41d ago

CAMP4 to Participate in Upcoming Investor Conferences

thenewswire.com · 42d ago

Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec

thenewswire.com · 56d ago

Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec

zacks.com · 60d ago

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

globenewswire.com · 60d ago

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

cnbc.com · 67d ago

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

prnewswire.com · 68d ago

SIX FLAGS GREAT AMERICA ANNOUNCES CAMP TIMBER TRAIL, AN ALL-NEW FAMILY ADVENTURE FOR 2027

globenewswire.com · 70d ago

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

thenewswire.com · 77d ago

Canadian GoldCamps Completes Independent NI 43-101 Technical Report for the Mercator Gold Project

globenewswire.com · 78d ago

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

globenewswire.com · 87d ago

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 87d ago

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

zacks.com · 89d ago

New Strong Sell Stocks for July 16th

Market news & ticker search · RSS for CAMP

FAQ

What is LOPJLB’s current signal on CAMP?: LOPJLB’s latest quantitative signal on CAMP4 Therapeutics Corporation (CAMP) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is CAMP in?: CAMP4 Therapeutics Corporation (CAMP) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does CAMP4 Therapeutics Corporation (CAMP) do?: CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Docs Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener Best dividend stocks Undervalued stocks Best S&P 500 stocks

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

DATA 2026-10-09

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE